Description

Simple

Clinical

Overview

A synthetic estrogen that has been used as a hormonal antineoplastic agent.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Hexestrol
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
Hexestrol may decrease the anticoagulant activities of (R)-warfarin.
(S)-Warfarin
Hexestrol may decrease the anticoagulant activities of (S)-Warfarin.
4-hydroxycoumarin
Hexestrol may decrease the anticoagulant activities of 4-hydroxycoumarin.
Abciximab
Hexestrol may decrease the anticoagulant activities of Abciximab.
Abituzumab
Hexestrol may increase the thrombogenic activities of Abituzumab.
Abrilumab
Hexestrol may increase the thrombogenic activities of Abrilumab.
Aceclofenac
Aceclofenac may increase the thrombogenic activities of Hexestrol.
Acenocoumarol
Hexestrol may decrease the anticoagulant activities of Acenocoumarol.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hexestrol.
Acetylsalicylic acid
Hexestrol may decrease the anticoagulant activities of Acetylsalicylic acid.
Adalimumab
Hexestrol may increase the thrombogenic activities of Adalimumab.
Adecatumumab
Hexestrol may increase the thrombogenic activities of Adecatumumab.
Aducanumab
Hexestrol may increase the thrombogenic activities of Aducanumab.
Afelimomab
Hexestrol may increase the thrombogenic activities of Afelimomab.
Aldosterone
The serum concentration of Aldosterone can be increased when it is combined with Hexestrol.
Alemtuzumab
Hexestrol may increase the thrombogenic activities of Alemtuzumab.
Alirocumab
Hexestrol may increase the thrombogenic activities of Alirocumab.
Alteplase
Hexestrol may decrease the anticoagulant activities of Alteplase.
Amatuximab
Hexestrol may increase the thrombogenic activities of Amatuximab.
Amediplase
Hexestrol may decrease the anticoagulant activities of Amediplase.
1 References
  1. 1 . Liehr JG, Ballatore AM, Dague BB, Ulubelen AA: Carcinogenicity and metabolic activation of hexestrol. Chem Biol Interact. 1985 Oct;55(1-2):157-76.PubMed: 2998630